Identification of Plasma Biomarkers in Drug-Naïve Schizophrenia Using Targeted Metabolomics
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Schizophrenia (SCZ) is a severe psychiatric disorder with unknown etiology and lacking specific biomarkers. Herein, we aimed to explore plasma biomarkers relevant to SCZ using targeted metabolomics. Methods Sixty drug-naïve SCZ patients and 36 healthy controls were recruited. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale. We analyzed the levels of 271 metabolites in plasma samples from all subjects using targeted metabolomics, and identified metabolites that differed significantly between the two groups. Then we evaluated the diagnostic power of the metabolites based on receiver operating characteristic curves, and explored metabolites associated with the psychotic symptoms in SCZ patients. Results Twenty-six metabolites showed significant differences between SCZ patients and healthy controls. Among them, 12 metabolites were phosphatidylcholines and cortisol, ceramide (d18:1/22:0), acetylcarnitine, and γ-aminobutyric acid, which could significantly distinguish SCZ from healthy controls with the area under the curve (AUC) above 0.7. Further, a panel consisting of the above 4 metabolites had an excellent performance with an AUC of 0.867. In SCZ patients, phosphatidylcholines were positively related with positive symptoms, and cholic acid was positively associated with negative symptoms. Conclusion Our study provides insights into the metabolite alterations associated with SCZ and potential biomarkers for its diagnosis and symptom severity assessment.
Abstract
Objective Schizophrenia (SCZ) is a severe psychiatric disorder with unknown etiology and lacking specific biomarkers. Herein, we aimed to explore plasma biomarkers relevant to SCZ using targeted metabolomics. Methods Sixty drug-naïve SCZ patients and 36 healthy controls were recruited. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale. We analyzed the levels of 271 metabolites in plasma samples from all subjects using targeted metabolomics, and identified metabolites that differed significantly between the two groups. Then we evaluated the diagnostic power of the metabolites based on receiver operating characteristic curves, and explored metabolites associated with the psychotic symptoms in SCZ patients. Results Twenty-six metabolites showed significant differences between SCZ patients and healthy controls. Among them, 12 metabolites were phosphatidylcholines and cortisol, ceramide (d18:1/22:0), acetylcarnitine, and γ-aminobutyric acid, which could significantly distinguish SCZ from healthy controls with the area under the curve (AUC) above 0.7. Further, a panel consisting of the above 4 metabolites had an excellent performance with an AUC of 0.867. In SCZ patients, phosphatidylcholines were positively related with positive symptoms, and cholic acid was positively associated with negative symptoms. Conclusion Our study provides insights into the metabolite alterations associated with SCZ and potential biomarkers for its diagnosis and symptom severity assessment.
참고문헌 (48)
- McGrath J, "Schizophrenia : a concise overview of incidence, prevalence, and mortality", Epidemiol Rev, 30, pp.67~76 (2008)
- Zhu MH, "Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia : a 12-week randomized, double-blind, placebo-controlled trial", Mil Med Res, 9, pp.59~ (2022)
- van Os J, "Schizophrenia", Lancet, 374, pp.635~645 (2009)
- Lieberman JA, "Early detection and preventive intervention in schizophrenia : from fantasy to reality", Am J Psychiatry, 176, pp.794~810 (2019)
- Chadeau-Hyam M, "Metabolic profiling and the metabolome-wide association study : significance level for biomarker identification", J Proteome Res, 9, pp.4620~4627 (2010)
- Roberts LD, "Targeted metabolomics", Curr Protoc Mol Biol, 98, pp.30~ (2012)
- Chen X, "Metabolomics study of oral cancers", Metabolomics, 15, pp.22~ (2019)
- Delplancke TDJ, "Metabolomics of pregnancy complications : emerging application of maternal hair", Biomed Res Int, 2018, pp.2815439~ (2018)
- Lai W, "Metabolomics provides novel insights into epilepsy diagnosis and treatment : a review", Neurochem Res, 47, pp.844~859 (2022)
- Hou XW, "Metabolomics in diabetic retinopathy : a systematic review", Invest Ophthalmol Vis Sci, 62, pp.4~ (2021)
- Sethi S, "Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders", World J Biol Psychiatry, 18, pp.506~520 (2017)
- Hashimoto K, "Metabolomics of major depressive disorder and bipolar disorder : overview and future perspective", Adv Clin Chem, 84, pp.81~99 (2018)
- Du Y, "Metabolomic identification of serum exosome-derived biomarkers for bipolar disorder", Oxid Med Cell Longev, 2022, pp.5717445~ (2022)
- Wang D, "Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia", Psychiatry Res, 272, pp.18~29 (2019)
- Weber-Fahr W, "Altered phospholipid metabolism in schizophrenia : a phosphorus 31 nuclear magnetic resonance spectroscopy study", Psychiatry Res, 214, pp.365~373 (2013)
- Hamazaki K, "Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder : no changes in docosahexaenoic acid species", J Psychiatr Res, 44, pp.688~693 (2010)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
- Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Rodriguez-Jimenez R, "Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia", Schizophr Res, 143, pp.77~83 (2013)
- Mahadevan S, "Analysis of metabolomic data using support vector machines", Anal Chem, 80, pp.7562~7570 (2008)
- Tessier C, "Membrane lipidomics in schizophrenia patients : a correlational study with clinical and cognitive manifestations", Transl Psychiatry, 6, pp.e906~ (2016)
- Yang X, "Serum fatty acid patterns in patients with schizophrenia : a targeted metabonomics study", Transl Psychiatry, 7, pp.e1176~ (2017)
- Sethi S, "Lipidomics, biomarkers, and schizophrenia : a current perspective", Adv Exp Med Biol, 965, pp.265~290 (2017)
- Kaddurah-Daouk R, "Metabolomic mapping of atypical antipsychotic effects in schizophrenia", Mol Psychiatry, 12, pp.934~945 (2007)
- Schwarz E, "High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides", J Proteome Res, 7, pp.4266~4277 (2008)
- Leppik L, "Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis", Eur Arch Psychiatry Clin Neurosci, 270, pp.59~70 (2020)
- Fukuzako H, "Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients", Am J Psychiatry, 156, pp.1205~1208 (1999)
- Ghosh S, "Evidence for altered cell membrane lipid composition in postmortem prefrontal white matter in bipolar disorder and schizophrenia", J Psychiatr Res, 95, pp.135~142 (2017)
- Hasegawa H, "Lysophosphatidylcholine enhances the suppressive function of human naturally occurring regulatory T cells through TGF-β production", Biochem Biophys Res Commun, 415, pp.526~531 (2011)
- Janssen CI, "Long-chain polyunsaturated fatty acids(LCPUFA)from genesis to senescence : the influence of LCPUFA on neural development, aging, and neurodegeneration", Prog Lipid Res, 53, pp.1~17 (2014)
- Girshkin L, "Morning cortisol levels in schizophrenia and bipolar disorder : a meta-analysis", Psychoneuroendocrinology, 49, pp.187~206 (2014)
- Mück-Seler D, "Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients", Biol Psychiatry, 45, pp.1433~1439 (1999)
- Pinto JV, "On the transdiagnostic nature of peripheral biomarkers in major psychiatric disorders : a systematic review", Neurosci Biobehav Rev, 83, pp.97~108 (2017)
- Smesny S, "Skin ceramide alterations in first-episode schizophrenia indicate abnormal sphingolipid metabolism", Schizophr Bull, 39, pp.933~941 (2013)
- de Almeida V, "Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients", Prog Neuropsychopharmacol Biol Psychiatry, 101, pp.109945~ (2020)
- Cao B, "Characterizing acyl-carnitine biosignatures for schizophrenia : a longitudinal pre-and post-treatment study", Transl Psychiatry, 9, pp.19~ (2019)
- Cui G, "Serum metabolomic profiling based on Fourier transform-ion cyclotron resonance-mass spectrometry : do the dysfunctions of metabolic pathways reveal a universal risk of oxidative stress in schizophrenia?", Antioxid Redox Signal, 33, pp.679~688 (2020)
- Chiu PW, "In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia : a proton magnetic resonance spectroscopy study", Schizophr Res, 193, pp.295~303 (2018)
- He Y, "Schizophrenia shows a unique metabolomics signature in plasma", Transl Psychiatry, 2, pp.e149~ (2012)
- Xuan J, "Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action", J Proteome Res, 10, pp.5433~5443 (2011)
- Mason JW, "Multidimensional hormonal discrimination of paranoid schizophrenic from bipolar manic patients", Biol Psychiatry, 29, pp.457~466 (1991)
- Bujak R, "Metabolomics for laboratory diagnostics", J Pharm Biomed Anal, 113, pp.108~120 (2015)
- Li S, "Diabetes mellitus, cognitive deficits and serum BDNF levels in chronic patients with schizophrenia : a case-control study", J Psychiatr Res, 134, pp.39~47 (2021)
- Fu S, "Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity", Nature, 473, pp.528~531 (2011)
- Li Q, "Effects of dietary phosphatidylcholine and sphingomyelin on DSS-induced colitis by regulating metabolism and gut microbiota in mice", J Nutr Biochem, 105, pp.109004~ (2022)
- Khosravi M, "Ursodeoxycholic acid augmentation in treatment-refractory schizophrenia : a case report", J Med Case Rep, 14, pp.137~ (2020)
- Pollak TA, "The blood-brain barrier in psychosis", Lancet Psychiatry, 5, pp.79~92 (2018)
- Long SL, "Interactions between gut bacteria and bile in health and disease", Mol Aspects Med, 56, pp.54~65 (2017)